John A. Davis

3.5k total citations · 1 hit paper
65 papers, 2.7k citations indexed

About

John A. Davis is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, John A. Davis has authored 65 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 17 papers in Hematology and 15 papers in Oncology. Recurrent topics in John A. Davis's work include Protein Degradation and Inhibitors (18 papers), Acute Myeloid Leukemia Research (17 papers) and Pharmacogenetics and Drug Metabolism (7 papers). John A. Davis is often cited by papers focused on Protein Degradation and Inhibitors (18 papers), Acute Myeloid Leukemia Research (17 papers) and Pharmacogenetics and Drug Metabolism (7 papers). John A. Davis collaborates with scholars based in United States, Switzerland and Australia. John A. Davis's co-authors include James C. Sturm, David W. Inglis, Robert H. Austin, David A. Lawrence, Keith Morton, Stephen Y. Chou, Lotien Richard Huang, Dan A. Rock, Deborah A. Baker and Lee D. Arnold and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

John A. Davis

54 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deterministic hydrodynamics: Taking blood apart

2006 495 citations John A. Davis, David W. Inglis et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John A. Davis United States	25	928	625	531	298	294	65	2.7k
Xuefeng Wang China	30	550 0.6×	1.1k 1.8×	284 0.5×	307 1.0×	101 0.3×	170	3.2k
Tian‐Lu Cheng Taiwan	41	763 0.8×	2.1k 3.4×	987 1.9×	393 1.3×	247 0.8×	161	4.8k
Daniel J. O’Shannessy United States	38	699 0.8×	2.1k 3.4×	979 1.8×	480 1.6×	279 0.9×	80	4.6k
Sung Hee Lim South Korea	31	1.3k 1.4×	855 1.4×	1.1k 2.0×	853 2.9×	613 2.1×	119	3.5k
Andrew Riches United Kingdom	28	614 0.7×	1.3k 2.1×	279 0.5×	159 0.5×	86 0.3×	97	3.0k
James P. O’Connell United Kingdom	25	553 0.6×	1.1k 1.7×	652 1.2×	67 0.2×	182 0.6×	36	2.6k
Peipei Xu China	24	576 0.6×	800 1.3×	339 0.6×	315 1.1×	42 0.1×	159	2.2k
Ruimin Huang China	40	1.6k 1.7×	2.3k 3.7×	519 1.0×	357 1.2×	266 0.9×	139	5.0k
Yong Chen China	33	752 0.8×	1.7k 2.7×	179 0.3×	107 0.4×	365 1.2×	201	3.9k
Shiladitya Sengupta United States	32	1.5k 1.6×	1.6k 2.5×	839 1.6×	211 0.7×	75 0.3×	80	4.0k

Countries citing papers authored by John A. Davis

Since Specialization

Citations

This map shows the geographic impact of John A. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Davis more than expected).

Fields of papers citing papers by John A. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Davis. The network helps show where John A. Davis may publish in the future.

Co-authorship network of co-authors of John A. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Davis. A scholar is included among the top collaborators of John A. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Davis. John A. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fiskus, Warren, Christopher P. Mill, Christine Birdwell, et al.. (2025). Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models. Blood. 146(Supplement 1). 1497–1497.

Birdwell, Christine, Warren Fiskus, Christopher P. Mill, et al.. (2025). BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia. 40(2). 304–313.

Mill, Christopher P., Warren Fiskus, Christine Birdwell, et al.. (2024). ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents. Blood. 144(Supplement 1). 1349–1349. 1 indexed citations

Mill, Christopher P., Warren Fiskus, Courtney D. DiNardo, et al.. (2024). Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer Journal. 14(1). 25–25. 2 indexed citations

Fiskus, Warren, Lucia Masárová, Christopher P. Mill, et al.. (2024). Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase. Blood. 144(Supplement 1). 3142–3142.

Fiskus, Warren, Christopher P. Mill, Christine Birdwell, et al.. (2023). Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer Journal. 13(1). 53–53. 33 indexed citations

Birdwell, Christine, Warren Fiskus, Tapan M. Kadia, et al.. (2023). Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 38(3). 545–556. 5 indexed citations

Mill, Christopher P., Warren Fiskus, John A. Davis, et al.. (2023). Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 37(6). 1336–1348. 6 indexed citations

Fiskus, Warren, Christopher P. Mill, Christine Birdwell, et al.. (2023). Abstract 1140: Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML. Cancer Research. 83(7_Supplement). 1140–1140.

10.

Fiskus, Warren, Christopher P. Mill, Christine Birdwell, et al.. (2023). Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1. Blood. 142(Supplement 1). 4160–4160.

11.

Fiskus, Warren, Lucia Masárová, Christopher P. Mill, et al.. (2023). Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase. Blood. 142(Supplement 1). 741–741. 1 indexed citations

12.

Fiskus, Warren, Steffen Boettcher, Naval Daver, et al.. (2022). Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer Journal. 12(1). 5–5. 73 indexed citations

13.

Mill, Christopher P., Warren Fiskus, Courtney D. DiNardo, et al.. (2021). Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 139(6). 907–921. 48 indexed citations

14.

Hanna, Imad, et al.. (2017). Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition. Xenobiotica. 48(3). 300–313. 26 indexed citations

15.

Alvarez‐Núñez, Fernando, Vincent Chow, Dominick Daurio, et al.. (2015). Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility. Journal of Pharmaceutical Sciences. 104(4). 1522–1532. 14 indexed citations

16.

Maxwell, Joseph R., Yu Zhang, W. A. Brown, et al.. (2015). Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. Immunity. 43(4). 739–750. 265 indexed citations

17.

Hoj, Jacob P., et al.. (2014). Cellular contractility changes are sufficient to drive epithelial scattering. Experimental Cell Research. 326(2). 187–200. 10 indexed citations

18.

Inglis, David W., et al.. (2007). Determining blood cell size using microfluidic hydrodynamics. Journal of Immunological Methods. 329(1-2). 151–156. 45 indexed citations

19.

Davis, John A., David W. Inglis, James C. Sturm, & Robert H. Austin. (2006). Continuous separation of serum from human whole blood within a microfluidic device. Bulletin of the American Physical Society. 1 indexed citations

20.

Inglis, David W., John A. Davis, Robert H. Austin, & James C. Sturm. (2006). Critical particle size for fractionation by deterministic lateral displacement. Lab on a Chip. 6(5). 655–655. 332 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact